These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29885012)

  • 1. Increase in glycated haemoglobin concentrations after unwarranted prescription changes.
    Bell DSH; Goncalves E
    Diabetes Obes Metab; 2018 Oct; 20(10):2510-2511. PubMed ID: 29885012
    [No Abstract]   [Full Text] [Related]  

  • 2. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
    Blonde L; Patel C; Bookhart B; Pfeifer M; Chen YW; Wu B
    Curr Med Res Opin; 2018 Jun; 34(6):1143-1152. PubMed ID: 29595326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Ghosh A; Gupta R; Misra A
    J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
    [No Abstract]   [Full Text] [Related]  

  • 4. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
    Powell J; Miller SA; Taylor JR
    South Med J; 2015 Feb; 108(2):82-90. PubMed ID: 25688892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
    Storgaard H; Gluud LL; Christensen M; Knop FK; Vilsbøll T
    BMJ Open; 2014; 4(8):e005378. PubMed ID: 25232561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
    Huang CH; Huang YY; Hsu BR
    Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
    Prescrire Int; 2015 Feb; 24(157):33-5. PubMed ID: 25802910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
    Seufert J
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S65-9. PubMed ID: 24481635
    [No Abstract]   [Full Text] [Related]  

  • 14. Using insulin in type 2 diabetes: in need of a renaissance?
    Kerr D; Olateju T
    J Diabetes Sci Technol; 2011 Jul; 5(4):829-33. PubMed ID: 21880221
    [No Abstract]   [Full Text] [Related]  

  • 15. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
    Skolnik N; Bonnes H; Yeh H; Katz A
    Postgrad Med; 2016 May; 128(4):356-63. PubMed ID: 27043045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.